Dementia with Lewy bodies (DLB) …

Neurobehavioral & Cognitive Disorders

Updated 04.07.2024
Released 06.21.2007
Expires For CME 04.07.2027

Dementia with Lewy bodies

Authors: Linda A Hershey MD PhD FAAN FANA, David G Lichter MD ChB

See Contributor Disclosures

Editor: Howard S Kirshner MD

Dementia with Lewy bodies

In This Article

Quick Link

Introduction

Overview

Dementia with Lewy bodies is an age-associated neurodegenerative dementia characterized by the postmortem findings of pathologically misfolded alpha-synuclein protein aggregations in the form of Lewy bodies and Lewy neurites in the CNS. The majority of patients with dementia with Lewy bodies also have a moderate to severe level of Alzheimer disease plaque and tangle pathology sufficient for a secondary neuropathological diagnosis of Alzheimer disease. Clinically, this syndrome is associated with a prominent dementia with simultaneous, or later developing, extrapyramidal symptoms (ie, parkinsonism); however, not all patients with dementia with Lewy bodies develop clinical parkinsonism. Other core clinical features include the presence of fluctuations in attentiveness, well-formed visual hallucinations, and rapid-eye movement sleep behavioral disorder. These clinical features and postmortem findings are often indistinguishable from those observed in patients with Parkinson disease who develop dementia, often several years after the onset of motor symptoms. Thus, Parkinson disease dementia and dementia with Lewy bodies exist on a clinicopathological spectrum of underlying alpha-synucleinopathy, and the clinical distinction based on the timing of dementia in relation to parkinsonism is currently under debate (the “1-year rule” has been proposed to distinguish the two) (68). There are no FDA-approved therapies for dementia with Lewy bodies, so treatment is largely symptomatic. Current research is focused on rapid diagnosis for implementing trials of emerging disease-modifying therapies targeting alpha-synuclein protein aggregation and propagation.

Key points

	• Dementia with Lewy bodies is a clinical diagnosis that is highly specific but moderately sensitive to postmortem finding of alpha-synuclein Lewy pathology in the neocortex.
	• Diagnosis is based on clinical history, examination, and ancillary tests to rule out alternative diagnoses, including other neurodegenerative conditions (eg, frontotemporal dementia, Alzheimer disease, Parkinson disease, etc.).
	• Clinically, dementia with Lewy bodies is distinguished from Parkinson disease dementia through the “1-year rule” according to the latest consensus criteria (68), where dementia with Lewy bodies has onset of dementia within, or prior to, 1 year from the onset of parkinsonism, and Parkinson disease dementia is characterized by dementia occurring greater than 1 year after a diagnosis of established Parkinson disease.
	• Parkinson disease dementia and dementia with Lewy bodies share some common genetic risks and prodromal symptoms and can sometimes be indistinguishable at autopsy; thus, Parkinson disease dementia and dementia with Lewy bodies are likely to coexist on a continuum of clinical manifestations of underlying alpha-synucleinopathy with different patterns of onset and progression. Patients with Parkinson disease dementia are usually older at the time of death than those who have dementia with Lewy bodies.
	• The majority of patients with clinical dementia with Lewy bodies are found to have sufficient amyloid-beta plaque and tau tangle pathology for a secondary neuropathological diagnosis of Alzheimer disease; thus, aging and Alzheimer disease-related pathology may be synergistic with synucleinopathy to result in clinical dementia with Lewy bodies.
	• Treatment of dementia with Lewy bodies is largely symptomatic. Clinical trials have shown that cholinergic therapies approved for Alzheimer disease may improve cognitive symptoms, as well as visual hallucinations and nighttime behaviors.
	• The presymptomatic phase of this disease is called mild cognitive impairment with Lewy bodies (MCI-LB). These patients have more neuropsychiatric symptoms than those with the mild cognitive impairment stage that precedes Alzheimer disease (MCI-AD). They also do worse on attention and visuospatial tasks and other non-memory tasks than MCI-AD patients.

Historical note and terminology

The term “dementia with Lewy bodies” has its origins from the initial descriptions of postmortem microscopic findings of eosinophilic intracellular proteinaceous neuronal inclusions in Parkinson disease by Fritz Heinrich Lewy in the early 20th century, which were eventually named after him (ie, Lewy bodies and Lewy neurites). These pathological findings are considered the hallmark and gold-standard for diagnosis of Parkinson disease. Advances in our knowledge of the underlying molecular substrate for Parkinson disease and related disorders have been rapid in the past few decades. Improved postmortem detection of Lewy bodies using immunohistochemistry found patients with dementia and wide-spread cortical Lewy bodies and Lewy neurites to be the second most common neuropathological substrate for aging-related dementia. There have been numerous terms used to describe the clinical syndrome associated with cortical Lewy body/Lewy neurite pathology. In 1995, the first dementia with Lewy bodies consortium meeting was held in Newcastle, United Kingdom to define clinical diagnostic criteria and terminology for dementia with Lewy bodies and to standardize pathological measures for improved diagnosis. Since that time, the consortium has met four times to refine criteria and pathological methods. The 4th International dementia with Lewy bodies Consortium meeting was held in December 2015 with the consensus report from this meeting reported by McKeith and colleagues (68). In 1997, two near-simultaneous reports found pathogenic mutations in the SNCA gene encoding alpha-synuclein protein in patients with hereditary Parkinson disease and pathogenic alpha-synuclein protein as the primary constituent of Lewy bodies/Lewy neurites in both Parkinson disease and dementia with Lewy bodies (77; 87). These two important studies demonstrated that abnormal aggregation of alpha-synuclein protein in the CNS is central to the disease process in Parkinson disease and dementia with Lewy bodies. Modern clinical diagnostic criteria use the terminology “dementia with Lewy bodies” to refer to the clinical syndrome that is specific for postmortem findings of cortical alpha-synuclein Lewy body/Lewy neurite pathology. Dementia in Parkinson disease, or Parkinson disease dementia, is common and often is clinically and pathologically indistinguishable from dementia with Lewy bodies (43); thus, the umbrella term “Lewy body dementias” is often used to encapsulate these two syndromes associated with cortical alpha-synuclein Lewy body/Lewy neurite pathology. Up to 50% of patients with sporadic Alzheimer disease have alpha-synuclein pathology at autopsy, often restricted to the amygdala (36), whereas Lewy bodies were detected in 63% of amygdala samples from patients with familial Alzheimer disease (59). The pathological term “Lewy body disease” refers to all forms of pathological alpha-synuclein in the form of Lewy bodies/Lewy neurites regardless of clinical phenotype. Alzheimer disease biomarkers have been identified in 25% of those who have dementia with Lewy bodies (93). Finally, multiple system atrophy is also characterized by alpha-synuclein pathology, but dementia and Lewy bodies are rare in multiple system atrophy. Instead, alpha-synuclein pathology is seen in oligodendrocytes (ie, glial cytoplasmic inclusions). Thus, the term “synucleinopathies” refers to all neuropathological diagnoses characterized by proteinaceous inclusions composed of alpha-synuclein protein (ie, Parkinson disease, Parkinson disease dementia, dementia with Lewy bodies, and multiple system atrophy).

Clinical manifestations

Presentation and course

Clinical dementia is central to the clinical diagnosis of dementia with Lewy bodies (Table 1). Cognitive impairment largely involves problems with frontal executive functioning and visuospatial abilities; however, there may also be episodic memory loss (68; 49). Executive impairments include difficulty with following multi-task commands, problems with working memory, and inhibition of incorrect responses. Examples of bedside cognitive testing that may be helpful include digit span (ie, how many digits can be verbally recited forward and reverse), oral trails (ie, alternating between letters and numbers verbally or graphically), verbal fluency tasks for phonemic deficits (ie, letter fluency; for example, the number of words beginning with a specific letter, such as “F” generated in 60 seconds) or categorical lexical retrieval targets (ie, number of words corresponding to a semantic category, such as “animals” or “tools” generated in 60 seconds). Visuospatial abilities may be probed either using constructional tasks, such as drawing a clock face or complex figure, or other measures of perceptual ability. Episodic memory impairments may be tested through use of list-learning tasks or structured narratives for delayed verbal recall and also through visual recall of a previously constructed design. Language impairments, in the form of difficulty with sentence processing and production, can be present and are likely related to involvement of frontal lobes in dementia with Lewy bodies (31). Cognitive impairments must be progressive (through serial examinations or historical report by caregiver) and reach severity sufficient to interfere with activities of daily living to consider a diagnosis of dementia with Lewy bodies. The first clinical symptoms of mild cognitive impairment, delirium, or psychiatric symptoms may precede the onset of dementia by 15 years or more (69). Patients with dementia with Lewy body who have positive CSF biomarkers for amyloid or tau show faster cognitive decline over 5 to 6 years than those whose biomarkers fall in the normal range (93). One study showed that older patients with dementia with Lewy bodies who have reduced cortical grey matter volume have faster cognitive decline than younger patients with dementia with Lewy bodies who have reduced subcortical grey matter volume (38).

Table 1. Diagnostic Criteria for Dementia with Lewy Bodies

Essential feature	• Progressive cognitive decline (especially executive and visuospatial functioning) with interference of activities of daily living consistent with dementia.
Core features	• Fluctuations in attention and concentration (eg, periods of marked change in attention, loss of train of thought) • Recurrent, spontaneous (not drug-induced), well-formed visual hallucinations • Spontaneous (not drug-induced) parkinsonism • REM sleep behavior disorder
Indicative biomarkers*	• Low dopamine transporter uptake in basal ganglia on nuclear imaging (ie, SPECT/PET) • Low uptake on MIBG myocardial scintigraphy • Alpha-synuclein seeding amplification assays • Plasma p-tau biomarker assay (for co-occurrence of Alzheimer disease) • Polysomnographic confirmation of REM sleep without atonia
Supportive features**	• Postural instability, repeated falls • Neuroleptic sensitivity • Hyposmia • Syncope or transient unexplained loss of consciousness • Severe autonomic dysfunction • Hallucinations in other nonvisual modalities • Systematized delusions • Depression and anxiety • Excessive daytime sleepiness
Supportive biomarkers	• Relative preservation of medial temporal lobe structure on CT/MRI imaging • Generalized low uptake on functional nuclear imaging with reduced occipital activity (SPECT/PET) • Prominent slow wave activity on EEG with transient temporal sharp waves or periodic fluctuations in reactivity.
Temporal sequence	• The 1-year rule helps differentiate dementia with Lewy bodies from dementia occurring in the setting of longstanding Parkinson disease dementia; dementia with Lewy bodies associated dementia should precede Parkinsonism or occur within 1 year from the onset of motor Parkinsonism.
Non-supportive features	• Prominent cerebrovascular disease on neuroimaging associated with focal neurologic signs • Presence of other brain disorder or medical diagnosis that could account for part or all of clinical symptoms • Parkinsonism that emerges only at the stage of severe dementia
Diagnostic categories	Probable dementia with Lewy bodies Essential feature + more than two core features + indicative biomarkers OR Essential feature + one core feature + more than one indicative biomarker Possible dementia with Lewy bodies Essential feature + one core feature + no indicative biomarkers Essential feature + no core features + more than one indicative biomarker
* Probable dementia with Lewy bodies should not be diagnosed on basis of biomarkers alone. ** Supportive features and biomarkers help diagnostic evaluation of dementia with Lewy bodies but do not have diagnostic specificity. Adapted from (68).

Parkinsonism. Over 80% of autopsy-confirmed patients with dementia with Lewy bodies eventually develop extrapyramidal symptoms consistent with Parkinson disease during the progression of dementia with Lewy bodies (42). However, parkinsonism is not necessary to meet formal dementia with Lewy bodies criteria if two or more other core features are present (Table 1). At the time of clinical presentation, parkinsonism was present in only 22% of Lewy body patients who reported to a large Italian memory clinic (22). Parkinsonism may take the form of bradykinesia, postural instability, rigidity, or tremor and should not be attributed to medication or other etiology (ie, spontaneous) (68). The rest tremor in early dementia with Lewy bodies is more likely to be bilaterally symmetrical and less likely to be unilateral, as it is in early Parkinson disease (22).

Fluctuations in cognition. These fluctuations are another core feature of dementia with Lewy bodies and range in expression from periods of excessive daytime sleepiness or periods of reduced attention (including being lost in a train of thought), to prolonged periods of unresponsiveness. If prolonged, these episodes of unresponsiveness can be mistaken for a transient ischemic attack or a complex-partial seizure. Cognitive fluctuations may be elicited through history provided by the caregiver, but they can be difficult to ascertain. Detection of fluctuations may be aided through the use of structured interview questionnaires, such as the Dementia Cognitive Fluctuations Scale (96; 62). One group of investigators found that younger patients with Lewy bodies were more likely to experience cognitive fluctuations; in addition, they had a slower rate of cognitive decline (38). Patients with dementia with Lewy bodies are also more likely than Alzheimer patients to present with delirium (with acute and fluctuating changes in attention and arousal, often precipitated by a medical or surgical illness) (79).

Visual hallucinations. These phenomena often occur in patients with dementia with Lewy bodies and include complex, vivid, well-formed hallucinations of people, animals, or children. They were reported in 42% of Lewy body patients at their first consultation in one large Italian series (22). The patient’s responses to these hallucinations are variable, but often they are not disturbing to them. Hallucinations in other modalities are less common but can occur, such as those involving auditory or tactile modalities. It is important to distinguish true hallucinations from delusions through careful history-taking. Indeed, systematized delusions are supportive for a diagnosis of dementia with Lewy bodies. It is not uncommon for patients with dementia with Lewy bodies to have delusions of strangers invading the home or delusional misidentification syndrome (eg, Capgras syndrome) (69). Some patients with dementia with Lewy bodies and Parkinson disease dementia experience minor visual hallucinations, such as “passage hallucinations,” which consist of shadows or the brief appearance of someone passing through the periphery of one’s visual field (57). Other examples of minor hallucinations are “presence hallucinations,” where the patient feels a vivid sense of another person’s presence in the room. Minor visual hallucinations in dementia with Lewy bodies are not associated with severity of global cognitive impairment but with impairment of visuoperceptual processes and abstract reasoning (11). In one longitudinal study of 488 patients with dementia with Lewy bodies, visual hallucinations developed earlier in women than in men (09). In another study, patients with Lewy body disease with visual hallucinations had worse cognition and worse motor scores than age-matched patients without hallucinations (25).

REM sleep behavior disorder. Active sleep, including loud vocalizations and extreme motor movements of punching and kicking, is characteristic of rapid eye movement sleep behavior disorder (08), which is now considered a core feature of dementia with Lewy bodies (68). The prevalence of this parasomnia in the general population is 0.4% to 0.5%, whereas the prevalence among Lewy bodies patients is 40% (08). Often patients with REM sleep behavior disorder may report a dream where they are fighting off an attacker or an animal. Bed partners may complain of being hit in the middle of the night or becoming injured, and it is not uncommon for a patient to report waking up on the floor due to the aberrant motor behavior. It is important to differentiate true rapid-eye movement sleep behavior disorder from other parasomnias. Formal polysomnogram displaying lack of atonia during REM sleep stages can help to confirm the diagnosis of REM sleep behavior disorder as an indicative biomarker of dementia with Lewy bodies. Interestingly, many patients may have idiopathic REM sleep behavior disorder years prior to developing symptoms of dementia with Lewy bodies. Most patients with idiopathic REM sleep behavior disorder followed longitudinally eventually develop clinical Parkinson disease or dementia with Lewy bodies with alpha-synuclein pathology at autopsy (39; 09; 13). In a large, longitudinal study of patients with idiopathic REM sleep disorder, 73.5% converted to either Parkinson disease or dementia with Lewy bodies by the end of a 12-month follow-up period (78). In another longitudinal study, men were more likely to develop REM sleep behavior disorder earlier in the course of dementia with Lewy bodies than women (09).

Other clinical features considered suggestive for a clinical diagnosis of dementia with Lewy bodies include severe sensitivity to neuroleptic agents. Patients may become excessively somnolent for prolonged periods after exposure to low doses of typical neuroleptics (especially typical agents with high D2 receptor affinity), and there is risk of worsening parkinsonism and serious autonomic impairments similar to neuroleptic malignant syndrome; thus, a trial of neuroleptic medication should not be considered for diagnostic purposes. Clinical dementia with Lewy bodies may also have varying degrees of other non-motor symptoms related to deposition of alpha-synuclein pathology in the peripheral autonomic nervous system, including constipation, rhinorrhea, orthostatic hypotension, and erectile dysfunction (78; 03). Finally, depression and anxiety commonly occur near the onset of cognitive difficulties and are supportive features of dementia with Lewy bodies. When mild cognitive impairment groups were compared (those preceding Lewy body disease and those preceding Alzheimer disease), patients with mild cognitive impairment with Lewy bodies were shown to have more neuropsychiatric symptoms than those with mild cognitive impairment with Alzheimer disease (93).

Prodromal dementia with Lewy bodies. A current goal of research in dementia with Lewy bodies is identifying patients with presymptomatic disease who are in an early stage of dementia with Lewy bodies, including patients with mild cognitive impairment at risk for dementia, with the presence of these clinical features suggestive and supportive of dementia with Lewy bodies to improve diagnosis (17; 68; 69). One group of investigators identified a group of 148 patients with prodromal dementia with Lewy bodies who had either subjective cognitive impairment or mild cognitive impairment and two core features of dementia with Lewy bodies (03). Compared to a control group of subjective cognitive impairment and mild cognitive impairment patients with only one core dementia with Lewy bodies feature, these patients had slower verbal processing, more apathy, and more autonomic complaints. In three studies, patients with prodromal dementia with Lewy bodies showed hypometabolism on FDG-PET in posterior cortical areas, whereas patients with prodromal Alzheimer disease had hypometabolism in hippocampal and parahippocampal regions (52; 64; 102).

Prognosis and complications

Dementia with Lewy bodies is an incurable illness with no disease-modifying therapies currently available to alter the progression. Prognosis varies between individuals with a disease duration ranging from less than 1 year to over a decade in some cases. There are currently no prognostic markers validated for clinical use, and serial examinations for progression of cognitive and motor function are useful to help prepare families for next steps in supportive care through increased supervision and assistance with activities of daily living. Prevention of falls and aspiration and safety issues from cognitive impairment, such as wandering or leaving the stove on, are important to help reduce morbidity.

Neuropsychological changes. At baseline, patients in the mild cognitive impairment stage of Lewy body disease had fewer memory problems than an age-matched and cognitively matched group of patients with mild cognitive impairment who had prodromal Alzheimer disease (94; 35; 49). Copying abilities are equally reduced in patients with Alzheimer disease and dementia with Lewy bodies (50), but perception of fragmented letters by patients in the mild to moderate stages of dementia with Lewy bodies is more impaired than in those who are in similar stages of Alzheimer disease (83). The fragmented letters test proved to be a useful tool to gauge the severity of alpha-synuclein pathology in patients with dementia with Lewy bodies. Patients with mild cognitive impairment with Lewy bodies progressed faster over 3 years on attention tasks than patients with mild cognitive impairment with Alzheimer disease, whereas patients with mild cognitive impairment with Alzheimer disease declined faster on memory tasks and on a global cognitive task (MMSE) (94). In a similarly designed study, Hamilton and colleagues found that the mild cognitive impairment with Lewy bodies patients had a more rapid decline in visuospatial skills, whereas both groups progressed similarly with regard to language, memory, and executive functions (35). Those who have dementia with Lewy bodies progress on the MMSE at a rate of about 2.7 points per year and on the Dementia Cognitive Fluctuations Scale at about 2.6 points per year (62).

Clinical vignette

A 68-year-old male developed difficulty with memory and multitasking over the course of the past 2 years and presented to the clinic for cognitive evaluation. The symptoms had been causing significant anxiety and frustration and were reported to interfere with his ability to maintain appointments and pay bills. Doing simple calculations and organizational tasks in the home took much longer than they did previously. His wife had noticed these changes and found errors in his record-keeping for their finances and had taken over this responsibility as well as supervising his medication administration. He also noted that he had difficulty finding words and finishing sentences at times. The patient had been less motivated for social activities and his hobbies and was more content to stay home and watch TV for most of the day. Near the onset of these difficulties, he reported seeing shadows moving at night in the room when there was nothing there. At the time of presentation, he reported occasionally seeing children playing in their living room; he noted that this was not particularly disturbing to him and that he did not believe they were truly present.

The patient’s wife reported that he could separately have episodes of agitation due to the perception of invaders in their home and that his cognitive symptoms could wax and wane throughout the day (not just in the evening) such that he experienced extreme confusion with incoherent speech for periods of time ranging from a few minutes to hours. His wife also noticed in the past few months that his walking had become slow and that he had been off-balance. On review of systems, he had experienced active sleep for the past 10 years. This included sudden jerking movement of his limbs, loud vocalizations, and punching behavior. This had been concerning to his wife as she had been hit by him in the past. The patient underwent a sleep polysomnogram confirming rapid-eye movement sleep behavior disorder.

On examination, the patient had slow hypophonic speech with word-finding pauses and circumlocutions. He largely maintained attention throughout the exam with good effort, but there were periodic fluctuations in concentration during tasks that often required repetition of instructions to maintain set. There was reduced verbal fluency (6 “F” words in 60 seconds without a clear phonetic or semantic strategy) and digit span and poor performance on an oral trail task. His delayed recall of a list of six words was four with fair recognition. There was difficulty with visual construction of a complex figure and impaired perception of line orientation.

Lewy body dementia: visual perception

Examination of 68-year-old patient showed difficulty with visual construction of a complex figure and impaired perception of line orientation. (Contributed by Dr. David J Irwin.)

Elemental neurologic examination revealed bradykinesia with decrement on fine movements and rare myoclonic jerks. There was increased tone in the arms and legs with some cog-wheeling. There was no rest tremor, but a fine postural tremor. There was a parkinsonian gait with anteroflexed posture and short steps. Pull-back test found evidence of postural instability with three to four steps correction.

The diagnosis of dementia with Lewy bodies was considered, as the patient had dementia in addition to all four of the core features (parkinsonism, visual hallucinations, cognitive fluctuations, and rapid eye movement sleep behavior disorder, which is sufficient for the diagnosis of probable dementia with Lewy bodies (Table 1). An MRI of the brain, lumbar puncture, and blood tests for common etiologies that could contribute to cognitive impairment or mimic dementia with Lewy bodies in this age range were performed. MRI of the brain revealed mild diffuse cortical atrophy with largely preserved hippocampal volumes. Laboratory tests revealed normal TSH, B12, LYME, ESR, RPR, and ANA from serum and normal CSF protein, glucose, IgG, and cytology helping to exclude non-neurodegenerative mimics of this disorder.

Lewy body dementia: diffuse cortical atrophy (MRI)

Brain MRI in 68-year-old patient revealed mild diffuse cortical atrophy with largely preserved hippocampal volumes. (Contributed by Dr. David J Irwin.)

The cognitive and motor difficulties progressed over the course of 4 years with increasing confusion, cognitive impairment, apathy, and motor disability. There was some stabilization of cognitive testing for approximately 1 year with use of an acetylcholinesterase inhibitor. There was a mild response of motor symptoms to levodopa. He also developed orthostatic hypotension and syncopal episodes, some of which lasted several hours and were likely to be cognitive fluctuations. In the fourth year of disease, he had reduced oral intake and complete disorientation. He entered hospice care for failure to thrive. At autopsy, there was a high burden of alpha-synuclein-positive Lewy bodies and Lewy neurites in the neocortex, consistent with a primary neuropathological diagnosis of Lewy body disease or dementia with Lewy bodies along with high levels of Alzheimer disease-associated tau tangles and amyloid plaques consistent with a secondary diagnosis of Alzheimer disease.

Lewy body dementia: Lewy bodies and Lewy neurites in neocortex on autopsy

At autopsy of elderly patient with Lewy body dementia, there was a high burden of alpha-synculein-positive Lewy bodies and Lewy neurites in the neocortex, consistent with a primary neuropathological diagnosis of Lewy body disease ...

* This vignette is a composite of the history, evaluation, and cause of several patients to protect identity of the patients.

Biological basis

Etiology and pathogenesis

Pathology. Postmortem findings of cortical and limbic Lewy bodies and Lewy neurites in neurons composed of pathological alpha-synuclein protein are the gold standard for diagnosis of dementia with Lewy bodies (68). Alpha-synuclein is a presynaptic protein thought to play a role in vesicular transport under normal conditions, but this protein undergoes several post-translational modifications and aggregates into Lewy bodies and Lewy neurites in dementia with Lewy bodies. Alpha-synuclein propagates across interconnected networks throughout the nervous system in a prion-like manner (18). Diagnostic accuracy appears to be affected by the degree of comorbid Alzheimer disease pathology and also the degree of cortical alpha-synuclein pathology (88; 86; 24). In one cohort, Lewy bodies were identified in 54% of brains that were pathologically diagnosed with Alzheimer disease but clinically diagnosed with frontotemporal dementia (86). This may have resulted from the fact that among their study participants, visual hallucinations were common when there was co-pathology of Alzheimer and Lewy body diseases. Autopsy findings of early dopaminergic degeneration in asymptomatic cases suggest a subclinical prodromal state of alpha-synuclein pathology (14), and experimental studies strongly link Lewy body formation to the degeneration of neurons in the substantia nigra (61). Furthermore, some patients with incidental Lewy pathology appear to have cortical distributions that deviate from Parkinson disease Braak stages, suggesting a preclinical state of dementia with Lewy bodies (27). Comparative autopsy studies of Parkinson disease dementia and dementia with Lewy bodies largely show similar distributions of alpha-synuclein pathology involving both subcortical and cortical regions at end-stage disease (43; 42; 95), reflecting the high association of clinical dementia with cortical alpha-synculein pathology (44; 42). Approximately 80% of patients with clinical dementia with Lewy bodies and 40% of patients with Parkinson disease dementia have sufficient amyloid-beta plaques and tau neurofibrillary tangles to meet pathological diagnostic criteria for a secondary diagnosis of medium to high level Alzheimer disease, and these patients also have a higher burden of cortical alpha-synuclein pathology compared to patients with alpha-synuclein pathology alone (42; 95; 47). Patients who have mixed Lewy body disease and Alzheimer disease have additional cortical thinning throughout the association cortices, compared to the thinning seen in either disease alone (50). Forty percent of patients with dementia with Lewy bodies have cerebral microbleeds that are identifiable on MRI, compared to 50% of Alzheimer patients and 15% of age-matched controls (16). Patients with dementia with Lewy bodies who have increased amyloid deposition on PET show signs of lower grey matter volumes in the inferior temporal cortices compared to those without increased amyloid (24). Despite these group-wide differences, Parkinson disease dementia and dementia with Lewy bodies appear to have no pathological substrates at end-stage disease that clearly substantiate the differentiation of these two clinical syndromes from one another during life; thus, these diseases are best considered a spectrum of synucleinopathy associated with dementia. It is possible that aging and Alzheimer disease pathology may influence the onset and spread of alpha-synuclein pathology (34; 75), but future work using in vivo markers of alpha-synuclein pathology are needed to test this hypothesis.

Alpha-synuclein. Novel experimental models have shown that preformed fibrils formed by recombinant alpha-synuclein alone can propagate and spread through anatomically connected regions of the CNS in a time- and dose-dependent manner in both transgenic mice harboring human disease-associated alpha-synuclein transgene (61) and nongenetically-altered mice (60) (ie, wild-type mice), resulting in reduced survival and a motor phenotype; thus, recapitulating human Parkinson disease-like synucleinopathy. Further, cell culture models demonstrate the ability of pathological misfolded alpha-synuclein seeds or pre-formed fibrils to propagate from neuron to neuron with toxic consequences (18). Finally, preparations of recombinant alpha-synuclein preformed fibrils have been shown to have varying resistance to protease treatment and propensities for transducing both pathological alpha-synuclein and tau pathology in cell models suggestive of strain-like properties of different species of pathological alpha-synuclein (34). These data suggest that alpha-synuclein misfolding and cell-to-cell transmission is central to the disease pathogenesis in Lewy body dementia and that other mechanisms of cell toxicity such as oxidative stress, synaptic dysfunction, disruption of axonal transport, and inhibition of protein degradation pathways are likely down-stream responses to aggregation and spread of pathological species of alpha-synuclein (43). The transmission hypothesis of alpha-synuclein pathology is reminiscent of the pathogenic mechanism of prion disease; however, there is no clear evidence of clinical infectivity of Parkinson disease, dementia with Lewy bodies, or Alzheimer disease (40), which is in sharp contrast to the definition of a prion (ie, proteinacious infectious particle). Current research strategies for therapeutic development include immunotherapy or other mechanisms to slow or halt the progression of pathological alpha-synuclein aggregation within the CNS (74; 92). CSF alpha-synuclein seeding amplification assays now allow the accurate diagnosis of dementia with Lewy bodies in the prodromal stages (29). These assays will be important in designing future clinical trials of disease-modifying therapies.

Beta-amyloid and tau. There is accumulating evidence to suggest that cognitive decline in those who have dementia with Lewy bodies is not primarily due to alpha-synuclein-driven neurodegeneration but that beta-amyloid and tau may also play a role (46; 100; 75; 103; 24). In a study, higher rates of hospitalization were seen in patients with dementia with Lewy bodies who had more neurofibrillary tangle pathology (46). In another study, patients with Lewy bodies who were amyloid-positive by either PET or CSF had worse performance on tests of general cognitive function compared to those who were tau positive (23). A subsequent study examined how the presence of amyloid (as measured by amyloid-PET) might influence the effect of dopamine transporter availability in the putamen in patients with Lewy body diseases (02). The authors found that the presence of amyloid was unrelated to parkinsonism score in both patients with dementia with Lewy bodies and Parkinson disease. CSF and plasma p-tau levels have been shown to be valid measures of the co-occurrence of Alzheimer disease in patients with dementia with Lewy body in several studies (23; 103; 29).

Genetics. Most cases of dementia with Lewy bodies are sporadic. Rare familial forms of dementia with Lewy bodies have been linked to pathogenic mutations and duplications or triplications of the SNCA gene encoding the alpha-synculein protein, but these are more likely to present as Parkinson disease. Genetic risk factors for dementia with Lewy bodies appear to include both Parkinson disease- and Alzheimer disease-associated genes (33). A genome-wide analysis showed that patients with familial dementia with Lewy bodies could develop the disease based on an Alzheimer disease risk factor (an APOE-e4 allele), or one of several Parkinson disease risk factors (glucocerebrosidase A1, GBA1; alpha-synuclein, SNCA) (73; 91; 33; 04). Not all Parkinson disease-associated genes appear to confer risk for dementia with Lewy bodies, suggesting that there are other genetic influences on the clinical expression of this alpha-synucleinopathy (06; 04). Homozygous mutations in the glucocerebrosidase A1 (GBA1) gene are associated with the lysosomal storage disease, Gaucher disease. Parkinsonism and postmortem alpha-synuclein pathology were noted in many patients surviving to adulthood with GBA mutations that led to findings of increased frequency of heterozygous GBA mutation carriers in clinical and pathological Parkinson disease and dementia with Lewy bodies populations (73). Based on these and other observations, it has been suggested that altered lysosomal autophagy pathways are important in the pathogenesis of various alpha-synucleinopathies. The TMEM175 gene locus plays a role in lysosomal acidification, leading to decreased proteolysis and the build-up of alpha-synuclein, which explains the shared risk of both dementia with Lewy bodies and Parkinson disease (99). Interestingly, heterozygous GBA mutation carriers are more frequently associated with dementia with Lewy bodies patients without secondary Alzheimer disease pathology (90; 42). In one dementia with Lewy bodies study where CSF real time quaking-induced conversion (RT-QIC) assays were performed, 100% of the GBA mutation carriers showed alpha-synuclein seeding activity, whereas this activity was only documented in 79% of the wild-type participants (07). The authors advocated for using this CSF assay to stratify newly enrolled Lewy body patients into future clinical trials of disease modifying therapies.

Epidemiology

Difficulties in diagnostic accuracy, often requiring evaluation at a tertiary medical center, and clinical and pathological overlap with Alzheimer disease and Parkinson disease make traditional epidemiology studies of dementia with Lewy bodies challenging. Thus, most estimates are likely lower than the true occurrence of dementia with Lewy bodies (84). Postmortem findings of alpha-synuclein pathology in dementia patients suggest that Lewy body dementia is the second most common neurodegenerative dementia diagnosis after Alzheimer disease. Population-based studies for clinical dementia with Lewy bodies estimate a range in prevalence of 0.1% to 2% of the general population and between approximately 3% and 30% of dementia populations. The incidence of clinical dementia with Lewy bodies is estimated to be 3.5 per 100,000 person-years, which increases rapidly with age to more than 30 per 100,000 person years in those older than 65 (85); thus, age is a strong risk factor for dementia with Lewy bodies. Dementia with Lewy bodies has been associated with increased frequency in male patients for reasons that are currently unclear, but this could be related to potential protective effects of estrogen on the development of synucleinopathy. Indeed, studies of environmental risk factors for dementia with Lewy bodies are scant, but some report that oophorectomy prior to the age of 45 is associated with increased risk of dementia with Lewy bodies (05). Other potential environmental risk factors included caffeine abstinence and previous diagnosis of anxiety or depression (05). In a European autopsy study, Jellinger found that the mean age at death among patients with dementia with Lewy bodies (79.8 years) was significantly lower than that seen in Parkinson disease with dementia (83.9 years) (47). Disease duration from the time of diagnosis was also shorter in dementia with Lewy bodies (6.7 years) than in Parkinson disease with dementia (9.2 years).

Differential diagnosis

Confusing conditions

The differential diagnosis of dementia with Lewy bodies largely is influenced by observations about the onset and rate of progression of disease by patients and families. For those patients with dementia with Lewy bodies who report a slow and subtle progression of cognitive and motor impairments over the course of years, it is important to exclude alternative age-associated neurodegenerative diseases such as Alzheimer disease, multiple system atrophy, and frontotemporal degeneration. Patients with Alzheimer disease may have more prominent episodic memory loss early in the course of their disorder, whereas prominent Parkinsonism is less common in Alzheimer disease (35). Frontotemporal degeneration is a heterogeneous disorder (41) and includes atypical Parkinsonian syndromes (progressive supranuclear palsy or corticobasal syndrome), which can clinically resemble dementia with Lewy bodies. In a pathological study of 126 frontotemporal lobe dementia cases, coexisting Lewy body disease was identified at autopsy in nine brains (7%), and three of these patients had parkinsonism (26). Family members carrying the C9orf72 expansion frequently present with psychosis, so during the early stages, patients with frontotemporal dementia could be confused with those who eventually develop dementia with Lewy bodies (12). Progressive supranuclear palsy typically has a characteristic oculomotility deficit for vertical saccades along with severe postural instability and axial rigidity, although there is significant heterogeneity in clinical presentation. Corticobasal syndrome usually can be distinguished from dementia with Lewy bodies by the presence of prominent lateralization of extrapyramidal signs and motor apraxia. Multiple system atrophy can also be mistaken for dementia with Lewy bodies, especially if cognitive difficulties are prominent early in the disease, which is not common in multiple system atrophy (55). Findings of severe autonomic dysfunction or prominent cerebellar signs are useful to differentiate multiple system atrophy from dementia with Lewy bodies.

Other causes of visual hallucinations. Charles Bonnet syndrome can cause formed or unformed visual hallucinations (people, faces, animals, flowers) in those who have had visual loss from macular degeneration, cataracts, or other chronic eye conditions (54). Complex hallucinations can occur with focal seizures in the presence of occipital lobe tumors or vascular malformations (EEG and MRI are needed to detect these findings). Hallucinogenic substances are also to be suspected as the cause of visual hallucinations, but onset is usually acutely tied to use of the hallucinogenic substance. Psychiatric illnesses, such as schizophrenia, are usually earlier in onset than dementia with Lewy bodies, and the hallucinations are auditory rather than visual (54). A subset of patients with frontotemporal dementia have been shown to develop auditory hallucinations early in the course of their disease; these hallucinations are specific for those with TDP-43 pathology and the C9orf72 repeat expansion (86).

Diagnostic workup

Structural imaging. MRI is a useful examination tool for vascular disease, structural changes (eg, tumor, hippocampal atrophy suggestive of Alzheimer disease, hot-cross bun sign suggestive of multiple system atrophy, hummingbird sign suggestive of progressive supranuclear palsy, pronounced frontotemporal atrophy associated with frontotemporal degeneration), cortical ribbon or thalamic hyper-intensities (suggestive of prion disease), and subcortical hyperintensities suggestive of inflammatory conditions or demyelination. Preservation of hippocampal integrity is supportive of dementia with Lewy bodies diagnosis, but due to the high rate of Alzheimer disease co-morbidity, hippocampal volume loss does not exclude a diagnosis of dementia with Lewy bodies. The presence of cerebral microbleeds in patients with dementia with Lewy bodies should not exclude the diagnosis (16). In patients with dementia with Lewy bodies who had microbleeds, the systolic blood pressure was higher on average (156 mmHg) than in those without microbleeds (135 mmHg). In prodromal dementia with Lewy bodies, the MRI showed evidence of widening of sulci in the occipital lobes, frontoinsular cortices, and olfactory sulci (03). Large areas of white matter hyperintensities should not exclude the diagnosis of dementia with Lewy bodies because patients with dementia with Lewy bodies with increased age and absence of the APOE-e4 allele have been shown to have higher white matter intensity volumes (24). One study showed that older patients with dementia with Lewy bodies had reduced cortical grey matter volumes, whereas younger ones were more likely to have reduced volumes in subcortical grey matter (38).

Laboratory testing. Routine serum studies for common metabolic and infectious etiologies contributing to cognitive impairment in this age range are useful, including a complete metabolic profile, sedimentation rate, and thyroid function studies. Additional laboratory studies should be tailored to the patient’s medical history and review of symptoms (eg, history of rheumatoid arthritis may prompt an expanded autoimmune serology).

CSF studies. In cases in which the disease course is rapidly progressive, a diagnostic lumbar puncture is essential to help differentiate dementia with Lewy bodies from rapid progressive dementia etiologies (51) and routine cell count, protein, glucose, IgG index, gram-stain, culture, and cytology. Further investigations may be useful, depending on the specific rapid progressive dementias suspected in the differential based on a thorough history and physical examination (eg, protein 14-3-3 or real time quaking-induced conversion (RT-QuIC) assay for prion disease [18], anti-NMDA receptor antibody for limbic encephalitis). CSF analysis for Alzheimer disease–associated Abeta and tau protein level changes is still considered a research adjuvant study supporting Alzheimer disease diagnostic criteria (45). Many patients with dementia with Lewy bodies have high CSF tau and low Abeta levels, usually intermediate to the elevated levels of Tau and low levels of Abeta in Alzheimer disease and normal levels in Parkinson disease (93; 103), likely reflecting the high rate of Alzheimer disease co-pathology in dementia with Lewy bodies. Thus, the presence of positive Alzheimer disease CSF biomarkers does not preclude a diagnosis of dementia with Lewy bodies. RT-QuIC assays have been shown to have high sensitivity and specificity for detecting misfolded alpha-synuclein in CSF in Parkinson disease, multiple system atrophy, and dementia with Lewy bodies (07; 18). The latter assay (the same assay that is used in prion diseases) has been shown to be accurate in the MCI stages of dementia with Lewy bodies (81).

EEG. An EEG may be useful to help detect complex-partial seizures or periodic discharges consistent with some forms of rapidly progressing dementias. Diffuse slowing of the background rhythm is common to all dementias but may be more prominent in dementia with Lewy bodies and coincide with cognitive fluctuations (68).

FDG-PET. PET CT imaging using fluorodeoxyglucose may be helpful to detect patterns of cortical hypometabolism suggestive of synaptic dysfunction in dementia with Lewy bodies, which includes prominent posterior parietal and occipital hypometabolism (30). Besides posterior hypometabolism, there are two other distinct patterns that distinguish patients with prodromal dementia with Lewy bodies from those with prodromal Alzheimer disease (52; 64). The “cingulate island sign” is highly specific (but not sensitive) for making a diagnosis of prodromal dementia with Lewy bodies. This sign means that there is relative sparing of metabolism (creating an “island”) in the posterior cingulate cortex compared to surrounding hypometabolism in occipital cortical areas. A more sensitive sign is the ratio of medial temporal/substantia nigra metabolism (the ratio is higher in prodromal dementia with Lewy bodies compared to the MCI that precedes Alzheimer disease). Hypermetabolic areas on FDG-PET (in amygdala and entorhinal cortices) have also been identified in other prodromal patients (those with isolated REM sleep behavior disorder who were classified as being “progressors” because they either developed parkinsonism or mild cognitive impairment over time). These areas of hypermetabolism were hypothesized to represent either the recruitment of compensatory mechanisms or the activation of microglia (13). Some authors have suggested that FDG-PET should be added as an outcome measure for clinical trials for patients with prodromal Lewy body dementia (58).

Dopamine transporter imaging. Abnormalities in the striatum on DAT scans are a biomarker for dementia with Lewy bodies (Table 1) and reflect presynaptic neuronal degeneration in striatal projections from the substantia nigra. In the setting of possible dementia with Lewy bodies, a positive scan can be useful to differentiate dementia with Lewy bodies from Alzheimer disease (67; 68), which would have a normal signal due to the absence of nigral pathology early in the disease. Of note, dopamine transporter imaging is not specific for synucleinopathies and can be seen in other forms of parkinsonism, including progressive supranuclear palsy and corticobasal syndrome. Furthermore, due to the potential differences in spread of alpha-synuclein pathology in dementia with Lewy bodies, not all patients may have sufficient nigral pathology at onset to produce an abnormal DAT scan. Thus, a negative scan does not preclude the diagnosis of dementia with Lewy bodies, but a positive scan in the setting of other key clinical characteristics can be useful (68). Lewy body patients who are amyloid positive have lower DAT activity levels in the anterior putamen, ventral putamen, and ventral striatum (100).

Cardiac innervation scintigraphy. Based on the postmortem findings of pathological alpha-synuclein in postganglionic sympathetic cardiac innervation in dementia with Lewy bodies patients, cardiac imaging using iodine-123 metaiodobenzylguanidine (MIBG) scintigraphy finds abnormalities in dementia with Lewy bodies (80; 63); however, caution in interpretation should be used in the setting of exposure to specific medications and cardiac disease, such as cardiomyopathy, that can influence results (68). A study showed that cardiac MIBG distinguished mild cognitive impairment with Lewy bodies from mild cognitive impairment with Alzheimer disease patients, with a specificity of 88% (80).

Amyloid PET. Finally, Abeta amyloid-PET imaging using an Abeta amyloid-specific radioligand is currently FDA-approved to aid in the diagnosis of Alzheimer disease through in vivo visualization of neuritic amyloid plaques (10). Due to the frequency of amyloid plaque formation in healthy aging, with advanced age the significance of a positive test result for a patient with normal cognition or mild cognitive impairment is unclear but considered to increase risk of progression to dementia (48). Furthermore, most patients with dementia with Lewy bodies have moderate to severe burden of plaque pathology at autopsy (42), and in vivo studies find that imaging with Abeta amyloid-PET and emerging tau specific PET tracer is frequently positive in dementia with Lewy bodies (53; 101; 23; 24); therefore, a positive PET Abeta scan does not preclude the diagnosis of dementia with Lewy bodies. Further studies of these imaging ligands in combination with other emerging biomarkers for Alzheimer disease and synucleinopathies will likely be helpful for diagnosis and prognosis of dementia with Lewy bodies and help reduce the need for ancillary tests described above to rule out alternative diagnoses.

Management

Cholinesterase inhibitors. There are currently no FDA-approved medications for dementia with Lewy bodies, and management is largely symptomatic or supportive. Implementation of increased supervision and structured activities throughout the day are critical to help keep patients engaged with cognitively stimulating activities and to reduce agitation and risk of safety issues. Clinical trials suggest acetylcholinesterase inhibitors such as rivastigmine (66; 21), galantamine (19), and donepezil (71; 70) may help to improve attention and concentration, as well as to reduce fluctuations, visual hallucinations, and caregiver burden. There also are data to suggest efficacy of memantine, a glutamate antagonist used for symptomatic treatment of Alzheimer disease, for global functioning in patients with dementia with Lewy bodies (20); the common co-occurrence of Alzheimer disease pathology in dementia with Lewy bodies also suggests there could be potential benefit of these Alzheimer disease symptomatic therapies that restore deficient neurotransmitters in dementia with Lewy bodies, but further studies are needed to confirm this. Wang and colleagues provide a systematic review of therapeutic trials in dementia with Lewy bodies (98).

Antipsychotic drugs. Agitation can often be managed without drugs through the use of behavior-modification strategies to help keep patients oriented and engaged in structured activities. For example, visual hallucinations can often be handled by reassuring the patient that the “visitors” are “our friends,” and that they mean no harm. Nevertheless, Walker and colleagues demonstrated that patients with dementia with Lewy bodies have higher psychiatric symptom scores than Alzheimer patients (97). They found that in the mild dementia stage, 16% needed neuroleptic medications for agitation, compared to only 4% of mild Alzheimer patients. The first step for managing agitation or delirium is to taper the patient off drugs that could be aggravating their agitation and confusion, such as anticholinergic agents (79). Refractory visual hallucinations or agitation that creates a safety hazard can potentially be cautiously treated with second-generation neuroleptics with minimal D2 receptor activity (eg, quetiapine or clozapine). The starting dose of quetiapine is usually 25 mg every night at bedtime to avoid excessive daytime sedation or dizziness (37). Kurlan and colleagues performed a small clinical trial to find the mean dose of quetiapine that would be most effective for managing agitation in patients with dementia (23 of their 40 patients had dementia with Lewy bodies) (56). They found that a mean dose of 120 mg/d was well tolerated and did not worsen the parkinsonism in the Lewy bodies patients. Families need to know about the current black box warning associated with neuroleptics in the elderly (because of increased risk of stroke and overall mortality) (65). Typical neuroleptics, such as haloperidol or injectable neuroleptics, are absolutely contraindicated in dementia with Lewy bodies due to risk of severe hypersensitivity reaction (68). Rothenberg and colleagues described four patients with dementia with Lewy bodies with psychosis who had not improved on traditional antipsychotic drugs but who experienced benefit from pimavanserin (fewer hallucinations and delusions with reduced agitation) (Rothenberg and others 2023).

Valproic acid. If patients with dementia with Lewy bodies on cholinesterase inhibitors continue to become agitated while they are taking low doses of quetiapine, the dose of quetiapine can be slowly increased. If increasing the dose of quetiapine causes the patient to experience more parkinsonism, then another way to manage the agitation is to add a low dose of oral valproic acid (37). Several trials have been done with valproic acid in agitated Alzheimer disease patients, but the drug has not been shown to be effective as monotherapy. When it is used in combination with other psychotropic drugs, on the other hand, low doses (250 mg bid) of divalproex have been demonstrated to be useful in preventing agitation in patients with dementia (15). Higher maintenance doses of intravenous valproic acid (1500 mg/day) are sometimes needed to manage agitation in patients who are critically ill and in the ICU (28).

Carbidopa-levodopa. A trial of carbidopa-levodopa may be useful in some patients with dementia with Lewy bodies to improve parkinsonism and alertness during the day (22; 37). An important consideration for patients with dementia with Lewy bodies when using levodopa is the risk of worsening agitation and visual hallucinations with high doses of levodopa. In the large outpatient clinic series of Farina and colleagues, the mean dose of levodopa for patients with dementia with Lewy bodies was low for this reason (303 mg/day), compared to the usual dose needed to treat Parkinson disease (22).

Zonisamide. A new adjunct to levodopa for managing the parkinsonism of dementia with Lewy bodies is the antiepileptic drug, zonisamide. It has been shown in a randomized, double-blind phase 2 study to be effective at a dose of 50 mg/day as an adjunct to levodopa; it carries little risk of producing agitation or visual hallucinations (72). The Lewy body patients enrolled in this trial had had motor symptoms for 3.5 years on average, and their mean dose of levodopa at the time of enrollment was 279 mg/day.

Melatonin. This supplement is effective for treatment of rapid-eye movement sleep behavior disorder in dementia with Lewy bodies patients. Melatonin carries less risk of cognitive, motor, and respiratory side effects, compared to the first-line therapy, clonazepam (01).

Outcomes

Dementia with Lewy bodies is currently an incurable condition that culminates in end-stage dementia. Associated sequelae include systemic infections, injury from falls, or aspiration due to neurogenic dysphagia. Prognosis is variable between individuals, with a mean duration of disease for autopsy-confirmed dementia with Lewy bodies roughly 6 years from the onset of symptoms, ranging from 1 to 14 years in one large study (42; 32). Variability in disease course may be influenced by the difficulties in making a diagnosis early in the disease, socioeconomic factors, genetic modifiers, or other medical comorbidities. In addition, the disease course may depend on whether dementia with Lewy bodies appears in its pure form or whether it is mixed with Alzheimer disease (patients with mixed disease have increased hospitalization rates) (46). Patients with dementia with Lewy bodies have double the rate of functional deterioration in activities of daily living at the end of life, compared to Alzheimer patients (32).

Media

References

01: Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med 2010;6(1):85-95.** PMID 20191945
02: Baik K, Cha J, Park M, et al. Distinct amyloid-dependent patterns of nigra dopamine depletion in Lewy body diseases. Front Aging Neurosci 2023;15:1196602. PMID 37614472
03: Blanc F, Bouteloup V, Paquet C, et al. Prodromal characteristics of dementia with Lewy bodies: baseline results of the MEMENTO memory clinics nationwide cohort. Alzheimers Res Ther 2022;14(1):96.** PMID 35854388
04: Blauwendraat C, Reed X, Krohn L, et al. Genetic modifiers of risk and age of onset in GBA-associated Parkinson’s disease and Lewy body dementia. Brain 2020;143(1):234-48. PMID 31755958
05: Boot BP, Orr CF, Ahlskog JE, et al. Risk factors for dementia with Lewy bodies: a case-control study. Neurology 2013;81(9):833-40. PMID 23892702
06: Bras J, Guerreiro R, Darwent L, et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet 2014;23(23):6139-46. PMID 24973356
07: Brockmann K, Quadalti C, Lerche S, et al. Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson’s disease and dementia with Lewy bodies. Acta Neuropathol Commun 2021;9(1):175.** PMID 34717775
08: Chan PC, Lee HH, Hong CT, Hu CJ, Wu D. REM sleep behavior disorder (RBD) in dementia with Lewy bodies (DLB). Behav Neurol 2018:9421098. PMID 30018672
09: Choudhury P, Graff-Radford J, Aarke JA, et al. The temporal onset of the core features in dementia with Lewy bodies. Alzheimers Dement 2022;18(4):591-601.** PMID 34761850
10: Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol 2012;11(8):669-78. PMID 22749065
11: D’Antonio F, Boccio M, DiVita A, et al. Visual hallucinations in Lewy body disease: pathophysiological insights from phenomenology. J Neurol 2022;269(7):3636-52.** PMID 35099586
12: Devenney EM, Ahmed RM, Halliday G, et al. Psychiatric disorders in C9orf72 kindreds: study of 1414 family members. Neurology 2019;93(23):1022. PMID 31792111
13: Diaz-Galvan P, Miyagawa T, Przybelski SA, et al. Brain glucose metabolism and nigrostriatal degeneration in isolated rapid eye movement sleep behavior disorder. Brain Commun 2023;5(1):fcad021. PMID 36844148
14: Dickson DW, Fujishiro H, DelleDonne A, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol 2008;115(4):437-44. PMID 18264713
15: Dolder CR, Nealy KL, McKinsey J. Valproic acid in dementia: Does an optimal dose exist? J Pharm Pract 2012;25(2):142-50. PMID 22095580
16: Donaghy PC, Firbank M, Mitra D, et al. Microbleeds in dementia with Lewy bodies. J Neurol 2020;267(5):1491-8. PMID 32016624
17: Donaghy PC, McKeith IG. The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimers Res Ther 2014;6(4):46. PMID 25484925
18: Dong TT, Satoh K. The latest research on RT-QuIC assays – a literature review. Pathogens 2021;10(3):305. PMID 33807776
19: Edwards K, Royall D, Hershey L, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dement Geriatr Cogn Disord 2007;23(6):401-5. PMID 17409748
20: Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9(10):969-77. PMID 20729148
21: Fallon SJ, Plant O, Tabi YA, Manohar SG, Husain M. Effects of cholinesterase inhibition on attention and working memory in Lewy body dementias. Brain Commun 2023;5(4):fcad207. PMID 37545547
22: Farina E, Baglio F, Caffarra P, et al. Frequency and clinical features of Lewy body dementia in Italian memory disorder clinics. Acta Biomed 2009;80(1):57-64.** PMID 19705622
23: Ferreira D, Przybelski SA, Lesnick TG, et al. Beta-amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology 2020;95(24):e3257-68.** PMID 32989106
24: Ferreira D, Przybelski SA, Lesnick TG, et al. Cross-sectional associations of beta-amyloid, tau, and cerebrovascular biomarkers with neurodegeneration in probable dementia with Lewy bodies. Neurology 2023;100(8):e846-59. ** PMID 36443011
25: Firbank MJ, Collerton D, Morgan KD, et al. Functional connectivity in Lewy body disease with hallucinations. Eur J Neurol 2024;31(2):e16115. PMID 37909801
26: Forrest SL, Crockford DR, Sizemova A, et al. Coexisting Lewy body disease and clinical parkinsonism in frontotemporal lobar degeneration. Neurology 2019;92(21):e2472-82. PMID 31019099
27: Frigerio R, Fujishiro H, Ahn TB, et al. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol Aging 2011;32(5):857-63. PMID 19560232
28: Gagnon DJ, Fontaine GV, Smith KE, et al. Valproate for agitation in critically ill patients: A retrospective study. J Crit Care 2017;37:119-25. PMID 27693975
29: Gibson LL, Abdelnour C, Chong J, Ballard C, Aarsland D. Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers. Curr Opin Neurol 2023;36(4):264-75.** PMID 37387459
30: Graff-Radford J, Murray ME, Lowe VJ, et al. Dementia with Lewy bodies: basis of cingulate island sign. Neurology 2014;83(9):801-9.** PMID 25056580
31: Grossman M, Gross RG, Moore P, et al. Difficulty processing temporary syntactic ambiguities in Lewy body spectrum disorder. Brain Lang 2012;120(1):52-60. PMID 21962945
32: Gu Y, Kociolek A, Fernandez KK, et al. Clinical trajectories at the end of life in autopsy-confirmed dementia patients with Alzheimer disease and Lewy bodies pathologies. Neurology 2022;98(21):e2140-9.** PMID 35379761
33: Guerreiro R, Escott-Price V, Darwent L, et al. Genome-wide association analysis of genetic correlation in dementia with Lewy bodies, Parkinson’s and Alzheimer’s diseases. Neurobiol Aging 2016;38:214.e7-214.e10.** PMID 26643944
34: Guo JL, Covell DJ, Daniels JP, et al. Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell 2013;154(1):103-17. PMID 23827677
35: Hamilton CA, Matthews FE, Donaghy PC, et al. Cognitive decline in mild cognitive impairment with Lewy bodies or Alzheimer disease: a prospective cohort study. Am J Geriatr Psychiatry 2021;29(3):272-84. PMID 32863138
36: Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 2000;10(3):378-84. PMID 10885656
37: Hershey LA, Coleman-Jackson R. Pharmacological management of dementia with Lewy bodies. Drugs Aging 2019;36(4):309-19. PMID 30680679
38: Inguanzo A, Poulakis K, Mohanty R, et al. MRI data-driven clustering reveals different subtypes of dementia with Lewy bodies. NPJ Parkinsons Dis 2023;9(1):5.** PMID 36670121
39: Iranzo A, Tolosa E, Gelpi E, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol 2013;12(5):443-53. PMID 23562390
40: Irwin DJ, Abrams JY, Schonberger LB, et al. Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. JAMA Neurol 2013a;70(4):462-8. PMID 23380910
41: Irwin DJ, Cairns NJ, Grossman M, et al. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol 2015;129(4):469-91. PMID 25549971
42: Irwin DJ, Grossman M, Weintraub D, et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol 2017;16(1):55-65. PMID 27979356
43: Irwin DJ, Lee VM, Trojanowski JQ. Parkinson's disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nat Rev Neurosci 2013b;14(9):626-36. PMID 23900411
44: Irwin DJ, White MT, Toledo JB, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012;72(4):587-98. PMID 23037886
45: Jack CR, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(3):257-62. PMID 21514247
46: James BD, Wilson RS, Capuano AW, et al. Hospitalization, Alzheimer’s disease and related neuropathologies, and cognitive decline. Ann Neurol 2019;86(6):844-52. PMID 31614018
47: Jellinger KA. Are there morphological differences between Parkinson disease-dementia and dementia with Lewy bodies? Parkinsonism Relat Disord 2022;100:24-32.** PMID 35691178
48: Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement 2013;9(1):e-1-16. PMID 23360977
49: Kang S, Yoon SH, Na HK, et al. Neuropsychological comparison of patients with Alzheimer’s disease and dementia with Lewy bodies. J Clin Neurol 2023;19(6):521-9. PMID 37455503
50: Kang SW, Jeon S, Yoo HS, et al. Effects of Lewy body disease and Alzheimer disease on brain atrophy and cognitive dysfunction. Neurology 2019;92:e2015-26. PMID 30944239
51: Kansal K, Irwin DJ. The use of cerebrospinal fluid and neuropathologic studies in neuropsychiatry practice and research. Psychiatr Clin North Am 2015;38(2):309-22. PMID 25998118
52: Kantarci K, Boeve BF, Przybelski SA, et al. FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. Neuroimage Clin 2021;31:102754. PMID 34252877
53: Kantarci K, Lowe VJ, Boeve BF, et al. AV-1451 tau and beta-amyloid positron emission tomography imaging in dementia with Lewy bodies. Ann Neurol 2017;81(1):58-67. PMID 27863444
54: Kizza J, Lu RJ, Zuflacht J, Bouffard M. Clinical reasoning: a 48-year-old woman with 6 months of vivid visual hallucinations. Neurology 2022;99(4):166-71. PMID 35577571
55: Koga S, Parks A, Uitti RJ, et al. Profile of cognitive impairment and underlying pathology in multiple system atrophy. Mov Disord 2017;32(3):405-13. PMID 27859650
56: Kurlan R, Cummings J, Raman R, et al. Quetiapine for agitation or psychosis in patients with dementia with dementia and parkinsonism. Neurology 2007;68(17):1356-63. PMID 17452579
57: Lenka A, Pagonabarraga J, Pal PK, et al. Minor hallucinations in Parkinson disease: a subtle symptom with major clinical implications. Neurology 2019;93(16):725.** PMID 31611321
58: Lichter DG, Hershey LA. Proposal to add FDG-PET as an outcome measure for clinical trials in patients with prodromal Lewy body dementia. Neurology 2023;101(15):666-7. PMID 37400241
59: Lippa CF, Fujiwara H, Mann D, et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 1998;153(5):1365-70. PMID 9811326
60: Luk KC, Kehm V, Carroll J, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012a;338(6109):949-53. PMID 23161999
61: Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 2012b;209(5):975-86. PMID 22508839
62: Matar E, White SR, Taylor JP, et al. Progression of clinical features in Lewy body dementia can be detected over 6 months. Neurology 2021;97(10):e1031-40. PMID 34404743
63: Matsubara T, Kameyama M, Tanaka N, et al. Autopsy validation of the diagnostic accuracy of 123-I-metaiodobenzylguanidine myocardial scintigraphy for Lewy body disease. Neurology 2022;98(16):e1648-59.** PMID 35256483
64: Mattioli P, Pardini M, Girtler N, et al. Cognitive and brain metabolism profiles of mild cognitive impairment in prodromal alpha-synucleinopathy. J Alzheimers Dis 2022;90(1):433-44. PMID 36155519
65: Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry 2015;72(5):438-45. PMID 25786075
66: McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356(9247):2031-6. PMID 11145488
67: McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007;6(4):305-13. PMID 17362834
68: McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies 4th consensus report of the dementia with Lewy bodies consortium. Neurology 2017;89(1):88-100. PMID 28592453
69: McKeith IG, Ferman TJ, Thomas AJ, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology 2020;94(17):743-55.** PMID 32241955
70: Mori E, Ikeda M, Iseki E, et al. Efficacy and safety of donepezil in patients with dementia with Lewy bodies: results from a 12-week multi-centre, randomized, double-blind, and placebo-controlled phase IV study. Psychogeriatrics 2024;24(3):542-54. PMID 38439118
71: Mori E, Ikeda M, Kosaka K, et al. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol 2012;71(1):41-52.** PMID 22829268
72: Murata M, Odawara T, Hasegawa K, et al. Adjunct zonisamide to levodopa for DLB parkinsonism: a randomized, double-blind phase 2 study. Neurology 2018;68(1):45-50. PMID 29367449
73: Nalls MA, Duran R, Lopez G, et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol 2013;70(6):727-35. PMID 23588557
74: Oertel W, Schulz JB. Current and experimental treatments of Parkinson disease: A guide for neuroscientists. J Neurochem 2016;139 Suppl 1:325-37. PMID 27577098
75: Pan L, Li C, Meng L, et al. Tau accelerates alpha-synuclein aggregation and spreading in Parkinson’s disease. Brain 2022;145(10):3454-71. PMID 35552614
76: Pervin F, Edwards C, Lippa CF. Dementia With Lew Body: Impacts of Surgery. Am J Alzheimers Dis Other Demen 2016;31(1):5-17. PMID 26006790
77: Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276(5321):2045-7. PMID 9197268
78: Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behavior disorder: a multicenter study. Brain 2019;142(3):744-59.** PMID 30789229
79: Richardson S, Lawson RA, Price A, Taylor JP. Challenges in diagnosis and management of delirium in Lewy body disease. Acta Psychiatr Scand 2023;147(5):475-80.** PMID 36281704
80: Roberts G, Durcan R, Donaghy PC, et al. Accuracy of cardiac innervation scintigraphy for mild cognitive impairment with Lewy bodies. Neurology 2021;96(23):e2801-11. PMID 33883238
81: Rossi M, Balardi S, Teunissen CE, et al. Diagnostic value of the CSF alpha-synuclein real-time quaking-induced conversion assay at the prodromal MCI stage of dementia with Lewy bodies. Neurology 2021;97(9):e930-40. PMID 34210822
82: Rothenberg KG, McRae SG, Dominguez-Colman LM, Shutes-David A, Tsuang DW. Pimavanserin treatment for psychosis in patients with dementia with Lewy bodies: a case series. Am J Case Rep 2023;24:e939806. PMID 37775968
83: Salmon DP, Smirnov DS, Coughlin DG, et al. Perception of fragmented letters by patients with pathologically confirmed dementia with Lewy bodies or Alzheimer disease. Neurology 2022;99(18):e2034-43. PMID 36028327
84: Savica R, Boeve BF, Logroscino G. Epidemiology of alpha-synucleinopathies: from Parkinson disease to dementia with Lewy bodies. Handb Clin Neurol 2016;138:153-8. PMID 27637957
85: Savica R, Grossardt BR, Bower JH, Boeve BF, Ahlskog JE, Rocca WA. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol 2013;70(11):1396-402. PMID 24042491
86: Scarioni M, Gami-Patel P, Timar Y, et al. Frontotemporal dementia: correlations between psychiatric symptoms and pathology. Ann Neurol 2020;87(6):950-61.** PMID 32281118
87: Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388(6645):839-40. PMID 9278044
88: Tiraboschi P, Attems J, Thomas A, et al. Clinicians' ability to diagnose dementia with Lewy bodies is not affected by beta-amyloid load. Neurology 2015;84(5):496-9. PMID 25552579
89: Tsuang D, DiGiacomo L, Bird TD. Familial occurrence of dementia with Lewy bodies. Am J Ger Psychiatry 2004;12(2):179-88. PMID 15010347
90: Tsuang D, Leverenz JB, Lopez OL, et al. GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology 2012;79(19):1944-50. PMID 23035075
91: Tsuang D, Leverenz JB, Lopez OL, et al. APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurol 2013;70(2):223-8. PMID 23407718
92: Valera E, Spencer B, Masliah E. Immunotherapeutic approaches targeting amyloid-beta, alpha-synuclein, and tau for the treatment of neurodegenerative disorders. Neurotherapeutics 2016;13(1):179-89. PMID 26494242
93: Van de Beek M, Ooms FAH, Ebenau JL, et al. Association of the ATN research framework with clinical profile, cognitive decline, and mortality in patients with dementia with Lewy bodies. Neurology 2022;98:e1262-72. PMID 35074893
94: Van de Beek M, van Steenoven I, van der Zande JJ. Prodromal dementia with Lewy bodies: Clinical characterization and predictors of progression. Mov Disord 2020;35(5):859-67. PMID 32048343
95: Walker L, Stefanis L, Attems J. Clinical and neuropathological differences between Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies – current issues and future directions. J Neurochem 2019;150(5):467-74.** PMID 30892688
96: Walker MP, Ayre GA, Cummings JL, et al. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. Br J Psychiatry 2000;177:252-6. PMID 11040887
97: Walker Z, McKeith I, Rodda J, et al. Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer’s disease: a cohort study. BMJ Open 2012;2(1):e000380. PMID 22318660
98: Wang HF, Yu JT, Tang SW, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 2015;86(2):135-43. PMID 24828899
99: Wightman DP, Savage JE, Tissink E, Romero C, Jansen IE, Posthuma D. The genetic overlap between Alzheimer’s disease, amyotrophic lateral sclerosis, Lewy body dementia, and Parkinson disease. Neurobiol Aging 2023;127:99-112. PMID 37045620
100: Yoo HS, Lee S, Chung SJ, et al. Clinical and striatal dopamine transporter predictors of beta-amyloid in dementia with Lewy bodies. Neurology 2020b;94(13):e1344-52. PMID 32086384
101: Yoo HS, Lee S, Chung SJ, et al. Dopaminergic depletion, beta-amyloid burden, and cognition in Lewy body disease. Ann Neurol 2020a;87(5):739-50. PMID 32078179
102: Yoon EJ, Lee JY, Kim H, et al. Brain metabolism related to mild cognitive impairment and phenoconversion in patients with isolated REM sleep behavior disorder. Neurology 2022;98(24):e2413-24. PMID 35437260
103: Zhang Q, Li J, Quan W, et al. CSF alpha-synuclein and tau as biomarkers for dementia with Lewy bodies: a systematic review and meta-analysis. Alzheimer Dis Assoc Disord 2022;36(4):368-73. PMID 36183420

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Linda A Hershey MD PhD FAAN FANA

Dr. Hershey of the University of Oklahoma Health Sciences Center has no relevant financial relationships to disclose.
See Profile
David G Lichter MD ChB

Dr. Lichter of SUNY University at Buffalo received honorariums from IQVIA, Inc and Kyowa Kirin for speaking engagements.
See Profile

Editor

Howard S Kirshner MD

Dr. Kirshner of Vanderbilt University School of Medicine has no relevant financial relationships to disclose.
See Profile

Former Authors

Ataf Chaudry MD
Faisal Khan MD
Daniel L Murman MD
Ann Marie Hake MD
David J Irwin MD
John Q Trojanowski MD PhD
Martin R Farlow MD

Patient Profile

Age range of presentation: 45 to 65+ years
Sex preponderance: male>female, >1:1
Heredity: Families exist where one or more persons meet both clinical and neuropathological criteria for dementia with Lewy bodies (Tsuang et al 2004). Genetic studies have demonstrated that patients with familial dementia with Lewy bodies may inherit the disease from an Alzheimer disease relative (via the APOE-e4 locus), or from a Parkinson disease relative (via one of many Parkinson disease gene loci, such as the glucocerebrosidase locus) (Nalls et al 2013; Tsuang et al 2012; Tsuang et al 2013; Guerreiro et al 2016).
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Dementia with Lewy bodies: 331.82
ICD-10: Dementia with Lewy bodies: G31.83
OMIM: SNCA: 163890

GBA1: 606463

APOE: 107741

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Dementia with Lewy bodies

Associated Disorders

Parkinson disease with dementia
Alzheimer disease

Differential Diagnosis

Parkinson’s disease dementia
Alzheimer’s disease
Frontotemporal dementia
Multiple system atrophy
Progressive Supranuclear Palsy
- Corticobasal syndrome
- Vascular dementia/parkinsonism
- Prion Disease
- Rapid progressive dementias/delirium (Metabolic, Infectious, Inflammatory, Toxic, Iatrogenic)

Also Relevant

Parkinson disease
Multiple system atrophy
Progressive supranuclear palsy
Corticobasal degeneration
Alzheimer disease

Dementia with Lewy bodies

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Table 1. Diagnostic Criteria for Dementia with Lewy Bodies

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Outcomes

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Metal neurotoxicity

Vascular cognitive impairment

Addictive disorders

Automatic-voluntary dissociation

Hemifacial spasm

Wilson disease

Pre-mild cognitive impairment

PART (Primary age-related tauopathy)

This is an article preview.
Start a Free Account
to access the full version.